Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.80 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.67 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.67 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.67 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.67 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.67 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.67 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.67 |
| ▸ | APP | P05067 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889633 | 0.89 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL14889944 | 0.89 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL14889631 | 0.89 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL14889737 | 0.89 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL2591336 | 0.89 | BACE1 (0.77) | BACE1BACE2PSEN1PSEN2APH1B | |
| SCHEMBL2591331 | 0.89 | BACE1 (0.77) | BACE1BACE2PSEN1PSEN2APH1B | |
| SCHEMBL18044374 | 0.88 | BACE1 (0.63) | BACE1BACE2PSEN1PSEN2APH1B | |
| SCHEMBL2595368 | 0.85 | BACE1 (1.00) | BACE1BACE2PSEN1PSEN2APH1B | |
| SCHEMBL360390 | 0.85 | BACE1 (1.00) | BACE1BACE2PSEN1PSEN2APH1B | |
| Formic Acid SCHEMBL15467674 | 0.83 | BACE1 (0.94) | BACE1BACE2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828350-B2 | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-28 | — | — | US | claimed |
| EP-2580200-B1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-14 | — | — | EP | claimed |
| US-20160152581-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2016-06-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152581-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885PSEN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.